Navigation Links
Chindex International, Inc. Announces Management Changes
Date:12/28/2011

BETHESDA, Md., Dec. 28, 2011 /PRNewswire-Asia/ -- Chindex International, Inc. (NASDAQ: CHDX), an American health care company providing health care services in China through the operations of United Family Healthcare, a network of private primary care hospitals and affiliated ambulatory clinics, today announced the appointment of Lawrence Pemble as Chief Operating Officer (while retaining his position as Chief Financial Officer of the Company's joint venture, Chindex Medical Limited) and Robert C. Low as Chief Financial Officer (while retaining his positions as Chief Accounting Officer and Controller), effective January 1, 2012.

Mr. Pemble holds a B.S. in Business and Accounting from the University of Phoenix, a B.A. in Chinese Studies and Linguistics from the State University of New York at Albany and an MBA from the University of Michigan. Mr. Low is a Certified Public Accountant and holds a B.A. in Economics from the University of Pennsylvania and an MBA from the University of Houston.

The changes are part of the Company's increased focus on strategic execution and the optimization of management's experience and resources. Roberta Lipson, President and CEO of Chindex, commented, "We are excited to announce an expanded leadership role for Mr. Pemble, who has extensive expertise in on-the-ground operations and the Company's expansion in China, while Mr. Low moves up to lead our financial functions."

About Chindex International, Inc.

Chindex is an American healthcare company providing healthcare services in China through the operations of United Family Healthcare, a network of private primary care hospitals and affiliated ambulatory clinics. United Family Healthcare currently operates in Beijing, Shanghai, Tianjin and Guangzhou. The Company also provides medical capital equipment and products through Chindex Medical Ltd., a joint venture company with manufacturing and distribution businesses serving both domestic China and export markets. With thirty years of experience, the Company's strategy is to continue its growth as a leading integrated healthcare provider in the Greater China region. Further company information may be found at the Company's website at http://www.chindex.com.

Contact:

ICR, Inc.
Ashley De Simone
(646) 277-1227


'/>"/>
SOURCE Chindex International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Chindex International, Inc. Announces Opening of Latest Premium Hospital in Tianjin
2. Chindex International, Inc. to Present at the 22nd Annual Oppenheimer Healthcare Conference
3. Chindex International, Inc. Reports Financial Results for the Third Quarter and First Nine Months of 2011
4. Chindex International, Inc. to Report Financial Results for the Third Quarter and First Nine Months of 2011
5. Chindex International, Inc. to Attend Nomura Healthcare Corporate Day
6. Chindex International, Inc. Announces Participation in Upcoming Investor Conferences
7. Chindex International, Inc. Reports Financial Results for the Second Quarter and First Half of 2011
8. Chindex International, Inc. to Report Financial Results for the Second Quarter and First Half of 2011
9. Naviscan Announces Partnership With Chindex Medical Limited for Mainland China, Hong Kong and Macau
10. Chindex International, Inc. Reports First Quarter 2011 Financial Results
11. Chindex International, Inc. Reports Financial Results for the Three and Nine Month Period Ended December 31, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... , Dec. 6, 2016  Arcturus Therapeutics, ... medicines company, announced today that it entered into ... RNA-based therapeutics for the treatment of NASH and ... therapeutic delivery platform LUNAR™ and UNA Oligomer chemistry. ... "Given Takeda,s long-standing commitment to and expertise in ...
(Date:12/6/2016)... 2016  Regulus Therapeutics Inc. (NASDAQ: ... and development of innovative medicines targeting microRNAs, today ... R&D day, held in New York ... anti-miR targeting microRNA-27 (miR-27) for the treatment of ... anti-miR targeting microRNA-17 (miR-17) for the treatment of ...
(Date:12/6/2016)... A new study released today by the ... the 340B Drug Pricing Program will continue to expand at ... expected to exceed $23 billion in total purchases at the ... current Medicare Part B drug reimbursement purchases over the next ... on analysis of data on total drug purchases through 340B ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... When it came time to blow out his candles on his ... the Pediatric Heart Transplant team at Joe DiMaggio Children’s Hospital surprised his family ... hospital’s 30th heart transplant recipient. , “He was playing at home, when we got ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... financial consultation services to residents in the Sacramento/Folsom region, is initiating a charity ... facility. , The Another Choice Another Chance treatment center in Sacramento works to ...
(Date:12/7/2016)... ... December 07, 2016 , ... AlignLife clinics nationwide are giving back to ... fortunate enough to receive bountiful gifts wrapped tightly under a Christmas Tree. AlignLife ... children of the world. , In exchange for generous donations, customers will receive a ...
(Date:12/7/2016)... OR (PRWEB) , ... December 07, 2016 , ... Sharon ... Water, Global Climate Change and Your Health on Voice of America, declared on her ... to call attention to the fact that when these bullies attack leaders in corporate ...
(Date:12/7/2016)... ... 2016 , ... Delete® - Tattoo Removal and Laser Salon Offers Delightful Holiday ... Up To 33% Off Botox® and Juvederm® Products Now Through December 31, 2016 , ... Delightful Deals on Botox® and Juvederm® just in time for the holiday party ...
Breaking Medicine News(10 mins):